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Abstract. – Background and Objectives:
Little is known about the impact of comorbid
psychiatric symptoms in health related quality of
life (HRQL) in persons with HIV infection. The
aim of this investigation was to describe depres-
sive symptoms and the impact in HRQL in HIV
infected people.
Materials and Methods: A cross-sectional
study over 150 HIV-outpatients in a tertiary hos-
pital was designed. Depression data were ob-
tained using the Beck Depression Inventory,
Second Edition (BDI-II) inventory. HRQL data
were collected by disease-specific questionnaire
MOS-HIV. Researchers’ team designed a specific
template to get rest of the data.
Results: Almost three-quarters of the popula-
tion were men. After adjusting for gender and
age, HIV-related symptoms and presence of de-
pression were found to be negatively associated
with all the Medical Outcomes Study HIV Health
Survey (MOS-HIV) general domains and in the
Physical Health Summary score and Mental
Health Summary score.
Conclusions: Optimization of HRQL is partic-
ularly important now that HIV is a chronic dis-
ease with the prospect of long-term survival.
Quality of life and depression should be moni-
tored in follow-up of HIV infected patients. Co-
morbid psychiatric conditions may serve as
markers for impaired functioning and well-being
in persons with HIV.
Key Words:
Quality of Life, Depressive Symptoms, HIV Infec-
tions/psychology, Life Change Events, Depression
Score.
Introduction
The World Health Organization defines Mental
Health as “an integral component of health
through which one realizes one’s own cognitive,
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affective and relational abilities. With a balanced
mental disposition, one is more effective in coping
with the stresses of life, can work productively and
fruitfully and is better able to make a positive con-
tribution to the community”1. In terms of the psy-
che, Mental Health includes; sadness, demoraliza-
tion, loss of self-esteem and lack of interest; in the
physical field it expresses itself as asthenia, ady-
namia, hypoactivity, anorexia, weight-loss and
sleep difficulties. Comorbidity with depression in
chronic physical illnesses such as arthritis, cancer,
heart disease, diabetes or HIV infection is well es-
tablished and persons with one or more chronic
illness present a greater risk of depression2,3. Al-
ternatively, comorbidity with depression worsens
the state of health in patients with chronic illness
and reduces levels of Health Related Quality of
Life (HRQL) in physical and mental domains2,4.
HIV infection causes a strong impact through-
out its entire process; recently the biological per-
spective has extended to include psychological
perspectives as well. Problems with mental
health related to HIV infection are quite fre-
quently due to stressful events such as the emo-
tional impact of diagnosis; possible rejection
from family, professional and social life; the fact
that discrimination and stigmatization are still as-
sociated with the disease; clinical manifestations;
chronic course of the disease and side-effects of
certain antiretroviral medications such as zidovu-
dine. Almost half of patients will require psycho-
logical treatment and a significant number will
demonstrate greater psychopathological distur-
bances than general population5-7.
Psychological manifestations most often asso-
ciated with HIV infection are depressive syn-
dromes, given that infection is a risk factor for
development of psychological pathology. In addi-
tion, high levels of depression have been found in
individuals with high-risk behaviours for HIV in-
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tion was made up of infected persons in regular
follow-up at our Hospital who agreed to partici-
pate in the study from March 2007 to April 2008.
A total sample of 150 outpatients was consecu-
tively selected after signing a Medical Consent
Form according to Declaration of Helsinki. 9
persons refused to participate in the study while
the selection (6 men and 3 women who had no
relationship to each other neither similar sociode-
mographic, epidemiological or clinical character-
istics) so we collected a total of 150 patients, af-
ter consulting with the Investigation Department.
A questionnaire was created to collect data
through instruments of measurement (question-
naires) of the variables that were to be analysed:
• Sociodemographic Variables: age, sex, marital
status, living with partner, educational level,
employment status.
• Clinical Variables: HIV transmission group,
AIDS classification (CDC -Centers for Dis-
ease Control and Prevention- criteria), anti-
retroviral treatment (ART) and symptoms re-
lated to HIV infection.
In order to evaluate the presence of depres-
sion, BDI-II (Beck Depression Inventory, Second
Edition) was implemented. The first version of
BDI was developed in the 1960s19, certain modi-
fications were made in order to ensure that the
questionnaire covered all the diagnostic criteria
of depressive disorders proposed by DSM-IV in
1994, which produced the second edition of the
questionnaire20. BDI-II is an instrument com-
posed of 21 items designed to identify depressive
symptoms and quantify their intensity in adults
and adolescents who are at least 13 years old. In
each item the person must select the option that
best corresponds to their mental state over the
past 2 weeks from four alternatives listed from
lesser to greater severity. Each item is scored
from 0 to 3 and, after adding the numbers togeth-
er, a total score of between 0 and 63 is reached in
order to later establish categories of depression
severity in accordance with the example model in
BDI-II: 0-13 points, minimum depression or no
depression; 14-19 points, mild depression; 20-28
points, moderate depression and 29-63 points, se-
vere depression. If the person chooses more than
one option in an item, greater severity is scored21.
The instrument has been adapted and validated
for Spanish population with a high internal con-
sistency (coefficient α, 0.87), having detected
that BDI-II measures a general dimension of de-
fection(8). The prevalence of depression among
HIV infected people, according to diverse series,
varies between 4% and 30% and affects women
and homosexuals more frequently5,8-10.
A diagnosis of depression is often complicated
since some of its symptoms can also be manifes-
tations of organic illnesses such as AIDS demen-
tia complex; dementia symptoms in the initial
stages of the disease; endocrine and metabolic
illnesses such as hypothyroidism; hypothalamic-
hypophyseal axis alterations; hypovitaminosis
and electrolyte disturbances; anaemia and cere-
bral afflictions (infections or neoplasias)5,8. Psy-
chiatric disorders may have repercussions on ill-
ness’ evolution due to lack of treatment adher-
ence or effects on the immune system which alter
NK lymphocyte function, increase CD8 lympho-
cytes and decrease CD4 lymphocytes levels8,11,12.
It is important to understand that the presence
of psychological morbidity has been associated
with poor HRQL in HIV infected patients, poor
prognosis, poor response by patient to antiretrovi-
ral treatment (ART) and less adherence to said
therapy. At the same time, a greater number of
psychiatric symptoms present in patients, worst
HRQL values13. There is a clear relationship be-
tween health perceived by the patient and psycho-
logical and emotional well-being, so that the in-
fection’s impact favours answers of anxiety and
depression in an almost systematic way, with neg-
ative repercussions on quality of life for HIV in-
fected patient, which are notably greater when the
disease is in the advanced stages14-16. Depression
affects all HRQL domains in HIV infected people
and has been established as a predictive factor of
changes in general health perceptions and emo-
tional well-being in these patient17,18 together with
social support, coping and counselling techniques.
Relationship between depressive symptoms
and HRQOL in HIV population had not been
documented in our region. Therefore, the aim of
this study was to analyze and describe psychoso-
cial state and depressive disorder, as well as de-
termine their existing relationships with HRQL
in a population sample of HIV infected people in
follow-up at a tertiary Spanish hospital.
Methods
A cross-sectional study was designed in HIV
outpatient in follow-up at Rio Hortega University
Hospital in Valladolid, Spain. The target popula-
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pression formed by two symptomatic dimensions
(one cognitive-affective and other somatic-moti-
vational) which are highly interrelated (correla-
tion coefficient, 0.68)22,23. BDI-II is one of the
most used instruments in depression evaluation
in clinics and research, as well as one of the most
resorted questionnaires in evaluating depression
in HIV infected population9.
Regarding HRQL, the disease-specific MOS-
HIV (Medical Outcomes Study HIV Health Sur-
vey) questionnaire was selected. It was developed
by Wu et al in 1991, through the Medical Out-
comes Study24. It consists of 35 items grouped in-
to 11 domains: General Health Perceptions, Pain,
Physical Functioning, Role Functioning, Mental
Health, Energy, Health Distress, Cognitive Func-
tioning, Overall Quality of Life and Health Tran-
sition. It is possible to obtain Physical Health
(PHS) and Mental Health (MHS) Summary
Scores through weighting coefficients. Scores
vary, reaching values between 0 (worst state of
health possible) and 100 (best state of health pos-
sible). The version used in Spain is version 2.1 of
the original questionnaire, adapted and validated
with high internal consistency (α Cronbach =
0.78-0.89)25,26.
Statistical Analysis
Patients were contacted in order to schedule a
personal interview where a trained interviewer
administered the aforementioned. A descriptive
profile analysis was carried out on the sample
and expressed as mean ± standard deviation
(SD), frequencies and percentages. Subsequently,
the association between the variables was studied
using a Chi square test with Fisher’s exact test
and differences between means were analysed
using Student’s t-test and ANOVA. Study find-
ings were analysed using Statistical Package for
Social Sciences (SPSS v.15.0 SPSS Inc® pack-
age, Chicago, IL, USA). Significance level was
considered for a p-value ≤0.05. HRQL analysis
was carried out in accordance with the indica-
tions of the original Authors27.
Results
A total of 150 outpatients were studied, of
whom 112 were male (74.7%) and 38 were
women (25.3%). The mean age of the group was
44.3 ± 8.3 years old with a median age of 44
years. The mean age in the male group was 44.8 ±
8.2 years old and in female group was 43 ± 8.8
years old with no differences found among them.
Of the 150 patients, 19 men (17% of males) and 5
women (13.2% of females) were over 50s. In re-
gard to educational background, 57.3% (N=86) of
the patients had a general basic education, mean-
ing that they had either started or completed mid-
dle-deemed-secondary studies. The most common
marital status was single (46%), followed by being
married (35%), with remaining segment (wid-
owed, separated, common law relationship) at
10% or less. Regarding residential and family sta-
tus, the most common scenario was living with
partner and/or children (48%), followed by living
with relatives (31.3%). Slightly more than a third
of our patients (35.3%) were pensioners or retirees
and a smaller proportion (13.3%) was included in
the unemployed/housewife/other category, with
51% gainfully employed.
The main HIV transmission group in our serie
was shared needle use among heterosexuals in-
travenous drug users (IDU) (38%, N=57), fol-
lowed by non-IDU heterosexual contact (35.3%,
N=53) and homosexual contact (18.7%, N=28).
Infection through blood transfusions were report-
ed at lesser rates (1.3%) and 6.7% of patients
were included in the group “transmission un-
known/other.” In the staging, our sample distrib-
uted homogeneously throughout the Centers for
Disease Control (CDC) classification categories:
one third of patients belonged to category A,
while 32% were in the European-AIDS-stage. In
our series, 84% (N=126) of patients were under-
going treatment with antiretrovirals, of which
half the patients were following a protease in-
hibitors (PI) based regimen and 39.7% followed
a non-analogues (NNRTI) based regimen.
State of health evaluation included the pres-
ence of concomitant symptoms, which revealed
that 15.3% of patients were asymptomatic at the
time of the study, as opposed to 64% that showed
between 1-4 symptoms and 20.7% that showed 5
or more symptoms (mean 2.8 ± 2.3; median 3;
rank 0-11). Overall, out of all the patients, 53.3%
presented lypodystrophy; 31.3% fatigue, 30.7%
insomnia, 29.3% sweating, 27.3% diarrhoea,
26.7% weight loss, 20% loss of appetite, 19.3%
pain of some kind throughout the study period,
11.3% asthenia, 9.3% vomiting, 8.7% changes in
taste, 8% hair loss, 7.3% fever and 5.3% frequent
memory loss.
The overall mean score in our sample in the
Beck Depression Inventory (BDI-II) was 11.9 ±
10.4 points. Majority of our patients (70.7%) pre-
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4sented either minimum or non-depression versus
18.7% of patients with moderate-severe depres-
sion. Sample distribution according to age and
sex is represented in Table I, in which moderate-
severe depression is present with greater frequen-
cy among women than man (23.7% vs. 16.9%).
Relation between depression level and sociode-
mographic variables is reflected in Table II. No
significant differences were found in these rela-
tionships.
In relating depression severity with HIV trans-
mission group, we found that 13.5% of patients
who contracted the infection through heterosexu-
al contact showed severe depression versus 7%
of those who were infected through needle shar-
ing between IDU and 3.4% of patients who con-
tracted the infection through homosexual contact.
However, 79.3% (N=23) of patients infected
through homosexual contact, 71.9% (N=41) in-
fected through intravenous drug use and 65.4%
infected through heterosexual contact were found
to be free of depression. No differences were
found regarding relationship between level of de-
pression and CDC infection stage.
The presence of infection related symptoms
correlated significantly with the level of depres-
sion, so that among the asymptomatic patients,
91.3% (N=21) remained free of depression; on
the other hand, 61.5% (N=8) of patients with se-
vere depression showed 5 or more depression re-
lated symptoms (p<0.001). The relationship of
each individual symptom with depression severi-
ty is reflected in Table III.
In analysing depression severity in the ART
patient group, we found that patients with NNR-
TI-based regimen were found to be free from de-
pression or experiencing minimum depression
with greater frequency than patients following a
PI-based regimen (78% vs. 60.3%), at the same
time, the frequency of severe and moderate de-
pression proved more common in patients with
PI-based regimen than NNRTI-based (11.1% vs.
8% and 17.5% vs. 8%, respectively).
Regarding the HRQL characterization in our
sample, mean scores in domains of MOS-HIV
were the following: General Health Perceptions
46.1 ± 24.2, Pain 79.4 ± 24.2, Physical Function-
ing 84.3 ± 19.7, Role Functioning 82.7 ± 32.2,
Social Functioning 88 ± 22.7, Mental Health
68.1 ± 21.8, Energy 63.8 ± 23.4, Health Distress
82.7 ± 20, Cognitive Functioning 84.6 ± 17.5,
Quality of Life 58.2 ± 20.9, Health Transition
54.8 ± 18.9. Overall mean PHS was 52.3 ± 8.8,
while the mean value obtained from MHS was
49.3 ± 9.9.
In establishing HRQL domain categoriza-
tion, we found that women showed significant
lower scores than men in Pain (p=0.038) and
Cognitive Functioning (p=0.037), with no dif-
ferences found in the remaining domains. Sin-
gle patients (p=0.020) and those who lived
alone (p=0.006) obtained greater scores in Gen-
eral Health Perceptions domain. In analysing
the relationship between other indicative fac-
tors of state of health in our population and the
HRQL domains measured by the MOS-HIV
questionnaire, we found that asymptomatic pa-
tients showed significantly higher scores in all
domains (p<0.001) except in Health Transition
(p=0,268). Patients who contracted HIV infec-
tion through needle sharing among IDU
showed lower scores in General Health Percep-
tions (p=0.034). However, scores in Pain, Phys-
ical Function and PHS domains were lower in
patients belonging to “transmission unknown”
group (p=0.034; p=0.002; p<0.001, respective-
ly). In studying our group distribution in terms
of CDC categories, we observed that patients in
stage C got higher scores in Mental Health
(p=0.023), Energy (p=0.023), Cognitive Func-
tioning (p=0.046), Quality of Life (p=0.018)
and MHS (p=0.025).
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Men Women ≤ 50 years > 50 years
Depression
level N % N % N % N % N %
Minimum 106 70.7 83 74.1 23 60.5 86 68.3 20 83.3
Mild 16 10.7 10 8.9 6 15.8 15 11.9 1 4.2
Moderate 15 10.0 10 8.9 5 13.2 13 10.3 2 8.3
Severe 13 8.7 9 8 4 10.5 12 9.5 1 4.2
Total 150 100.0 112 100 38 100 126 100 24 100
Table I. Characteristics of the study population in terms of depression level, age and sex.
Finally, and a very strong predictive sign,
patients free of depression or with minimal de-
pression obtained higher scores in all domains
of the questionnaire:General Health Percep-
tions (p<0.001), Pain (p=0.018), Physical
Functioning (p<0.001), Role Functioning
(p=0.031), Social Functioning (p<0.001), Men-
tal Health (p<0.001), Energy (p<0.001), Health
Distress (p<0.001), Cognitive Functioning
(p<0.001), Quality of Life (p<0.001), Health
Transition (p=0.022), PHS (p<0.001) and MHS
(p<0.001).
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Depression level
Minimum Mild Moderate Severe
N % N % N % N %
Marital Status
Single 52 49.1 7 43.8 6 40 4 30.8
Married 37 34.9 7 43.8 6 40 3 23.1
Widowed 6 5.7 0 0 1 6.7 2 15.4
Separated/divorced 9 8.5 0 0 2 13.3 3 23.1
Common-law relationship 2 1.9 2 12.5 0 0 1 7.7
Living Situation
Couple/children 50 47.2 8 50 9 60 6 46.2
Relatives 32 30.2 7 43.8 2 13.3 6 46.2
Alone/with friends/others 24 22.6 1 6.3 4 26.7 1 7.7
Educational Background
Basic studies‡ 61 57.5 10 62.5 7 46.7 8 61.5
Secondary and higher education 45 42.5 6 37.5 8 53.3 5 38.5
Employment Status
Unemployed/housewife/other 12 11.3 4 25 1 6.7 3 23.1
With income 57 53.8 8 50 7 46.7 5 38.5
Pensioner/retiree 37 34.9 4 25 7 46.7 5 38.5
Table II. Characteristics of depression level categorized according to sociodemographic variables.
‡
= Includes complete and incomplete primary education.
Depression level
Minimum Light Moderate Severe Significance
(N = 106) (N = 16) (N = 15) (N = 13) analysis
Symptoms N % N % N % N % p-value
Pain 14 13.2 3 18.8 7 46.7 5 38.5 0.011
Fever 5 4.7 1 6.3 1 6.7 4 30.5 0.058
Sweating 24 22.6 4 25 6 40 10 76.9 0.001
Diarrhoea 21 19.8 6 37.5 7 46.7 7 53.8 0.014
Vomiting 4 3.8 2 12.5 4 26.7 4 30.8 0.004
Loss of Appetite 14 13.2 4 25 3 20 9 69.2 < 0.001
Changes in taste 4 3.8 2 12.5 2 13.3 5 38.5 0.004
Insomnia 26 24.5 7 43.8 5 33.3 8 61.5 0.037
Memory Loss 3 2.8 1 6.3 2 13.3 2 15.4 0.119
Asthenia 9 8.5 4 25 1 6.7 3 23.1 0.115
Fatigue 28 26.4 7 43.8 6 40 6 46.2 0.242
Lipodystrophy 54 50.9 8 50 10 66.7 8 61.5 0.629
Table III. Characteristics of depression level related to the presence of symptoms (individual analysis by symptom).
6Discussion
Our patients’ profile approximately reflects
that of the Spanish National Registry of AIDS
Cases28, which guarantees the representativity
and validity of our sample.
The presence of depression is an independent
factor evaluated by various researchers and work-
groups in our field of study5,6,10,29-32. Our group
has noted some level of depression in 29.3% of
our patients, being moderate-severe in 18.7% of
all. This data is similar to findings by other Span-
ish population groups6,14,33, in spite of implement-
ing different evaluation instruments from our
group, which gives validity to our results. Al-
though research regarding depression in HIV pa-
tients is sparse, the diversity of the population
samples studied provides disparate data in terms
of the presence of depression, varying between
4% and 30%5,8-10. The overall mean score of our
population proved slightly less than that of Park-
Wyllie et al.34 in Toronto patients using the same
measuring instrument. Nevertheless, other stud-
ies point out the presence of depression in half of
the study population using a different scale15,29,35.
Wisniewski et al.10 in a series that included out-
patients in Baltimore, maintains that women
show levels of depression more often than men,
which agrees with our findings.
HRQL is influenced by various determinants
of psychological morbidity, and depression is
one of the most important of these factors30-32. In
our series, depression has constituted a signifi-
cant association in the 11 HRQL domains mea-
sured by the MOS-HIV questionnaire as well as
the Summary Scores. We have substantiated that
patients who were free of depression or with
minimum depression showed better scores than
other individuals studied. These findings have
been indicated by other research groups both na-
tional6,33 and international10,18,31,32,34 using either
the BDI-II depression inventory or another in-
struments. Majority of our patients showed non-
depression. Women, patients who presented a
greater number of associated symptoms and
those who contracted the infection through het-
erosexual contact showed moderate and severe
depression more often.
The findings suggest that in order to carry out
an overall evaluation of HRQL in the HIV infect-
ed people, the instruments used should be com-
plemented by the incorporation of specific mea-
surements in the cognitive and psychological
sphere through scales or evaluation question-
naires14,34. Sherbourne et al.16 state that as psy-
chological determinants in HIV population are
connected to lower levels of HRQL independent-
ly from infection itself and those conditions
should be early detected and treated16.
Given the serious repercussions carried by an
unstable frame of mind on HRQL in people with
HIV, it is important to incorporate Mental Health
Care in programs directed at these patients6,32,36.
Communication between medical teams in Infec-
tiology and Psychiatry benefits treatments de-
signed for both pathologies because appropriate
psychiatric intervention increases access to ART,
optimises adherence, improves quality of life and
decreases mortality. It is important to keep in
mind and to include the neuropsychological as-
pects associated with HIV infection in clinical
processes and research8,18.
In conclusion, HRQL research is an increas-
ingly relevant issue that is being developed con-
tinuously37. This study reflects the importance of
evaluating depressive symptoms and their impact
on HRQL in HIV infected patients, using ques-
tionnaires specifically devised for this population
group allowing detection of problems that tradi-
tional clinical indicators do not provide. Our
study shows depression as one of the most im-
portant predictive factors in HRQL and its detec-
tion and appropriate management allow us a bet-
ter control of HIV infection and, therefore, pre-
serve the well-being of our patients.
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